Q2 2013 Investor Conference Call Presentation Charts
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Q2 2013 Investor Conference Call Presentation Charts

  • 494 views
Uploaded on

Presentation charts for Q2 2013 Investor Conference Call on July 31, 2013

Presentation charts for Q2 2013 Investor Conference Call on July 31, 2013

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
494
On Slideshare
494
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
3
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Q2 2013 Results Investor Conference Call July 31, 2013 / Marijn Dekkers, CEO
  • 2. Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. • Q2 2013 Investor Conference Call • Marijn DekkersPage 2
  • 3. Page 3 Q2 2013 – Highlights  Life-Sciences with continued operational progress:  New pharma product sales significantly exceed expectations, driving pharma growth to 10% organically  CropScience grows profitably in overall favorable market environment  Full-year 2013 new pharma product sales target raised to ~€1.4bn  Weak performance at MaterialScience in a challenging market environment  Group sales organically +5%; reported EBIT +74%; adjusted* EBITDA slightly above prior-year level; core EPS +6%  Full-year 2013 Group outlook maintained even though increasingly ambitious • Q2 2013 Investor Conference Call • Marijn Dekkers *before special items
  • 4. Page 4 EBIT in € million +74% 1,287 740 Sales in € million % currency & portfolio adj. +5% 10,360 10,166 EBITDA adjusted** in € million +1% 2,1952,169 Core EPS in € +6% 1.54 1.45 *Prior-year figures restated **before special items Q2’13Q2’12* Q2’13Q2’12* Q2’13Q2’12* Q2’13Q2’12* Q2 2013 – Group Performance: Driven By Life-Sciences • Q2 2013 Investor Conference Call • Marijn Dekkers
  • 5. Q2 2013 – Regional Performance: Growth Led By Emerging Economies Page 5 Africa & Middle East Eastern Europe Emerging Economies Emerging Economies¹ +6% Others² +12% USA +1% Western Europe +4% Q2 2013 Group Sales by Region Group €10,360m; +5% ~1,100 +16% ~1,500 +2% ~400 -1%~700 +3% ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand In € million, ∆% yoy Fx adjusted 37% 11% 31% 21% Latin America Emerging Asia³ • Q2 2013 Investor Conference Call • Marijn Dekkers
  • 6. Q2 2013 – Cash Flow And Net Debt Development Page 6 +€1.5bn 9.0 GCF oFCF 1,680 Invest- ments 502 1,034 ∆ y-o-y +37% +8% NCF 1,536 +10% +13% March 31, 2013 June 30, 2013 7.5 Q2 2013 Cash Flow Net Debt Development Cash Flow in € million, Net Debt in € billion • Q2 2013 Investor Conference Call • Marijn Dekkers
  • 7. Q2 2013 – HealthCare: New Products and Consumer Care Drive Growth Page 7 *before special items Q2 2013 Sales Earnings1 Pharma +6% (+10%) Consumer Health +1% (+4%) 36% HealthCare €4,800m; +4% (+8%) 2,8311,969 Price 0% Volume +7% Fx -4% Portfolio 0% In € million, ∆% yoy, () = Fx & portf. adjusted Q2‘12 Q2‘13 Q2‘12 Q2‘13 810 921 438 407 +14% -7% 1,248 1,328 +6% 330 -8% 902 987 +9% 572 302 Adj. EBITDA* Adj. EBIT* 685 +20% • Q2 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.
  • 8. Q2 2013 – CropScience: Continued Good Momentum Page 8 Crop Protection +6% (+8%) Environmental Science +2% (+6%) Seeds +4% (+2%) Q2 2013 Sales Earnings1 In € million, ∆% yoy, () = Fx & portf. adjusted CropScience €2,392m; +5% (+7%) Price +2% Volume +5% Fx -3% Portfolio +1% 1,953 Q2‘12 Q2‘13 Q2‘12 Q2‘13 549 624 +14% 435 514 +18% Adj. EBITDA* Adj. EBIT* 193 246 • Q2 2013 Investor Conference Call • Marijn Dekkers *before special items 1 Prior-year figures restated.
  • 9. Q2 2013 - MaterialScience: Performance Down Year-Over-Year, Up Quarter-Over-Quarter Page 9 **CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations CAS** -6% (-4%) Q2 2013 Sales Earnings1 In € million, ∆% yoy, () = Fx & portf. adjusted *before special items MaterialScience €2,875m; -3% (-1%) Price -1% Volume 0% Fx -1% Portfolio 0% 1,546 664 IO*** -5% (-4%) Q2‘12 Q2‘13 Q2‘12 Q2‘13 Adj. EBITDA* Adj. EBIT* 383 274 -28% 223 112 -50% 493 172 • Q2 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated. Polyurethanes +2% (+3%) Polycarbonates -9% (-8%)
  • 10. FY 2013 Group Outlook – Maintained, Even Though Increasingly Ambitious After Q2 Results Page 10 20121 2013E Sales €39.7bn +4-5% to ~€40-41bn* adj. EBITDA €8.3bn mid-single-digit % increase Core EPS €5.30 high-single-digit % increase Sales ∆ Fx and portfolio adjusted, EBITDA before special items *Assuming average Fx rates of H1 2013 Outlook depends on specific planning assumptions as detailed in the Annual Report• Q2 2013 Investor Conference Call • Marijn Dekkers 1 2012 figures restated
  • 11. Q2 2013 Results Investor Conference Call July 31, 2013 / Marijn Dekkers, CEO